Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680686 | 0.87 | HTT (0.34) | OPRM1 | |
| SCHEMBL15804607 | 0.85 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL11916119 | 0.82 | SIGMAR1 (0.37) | SIGMAR1 | |
| SCHEMBL117945 | 0.82 | SIGMAR1 (0.41) | SIGMAR1 | |
| SCHEMBL1709040 | 0.81 | KDM4E (0.42) | SIGMAR1 | |
| SCHEMBL1106434 | 0.80 | L3MBTL3 (0.43) | SIGMAR1 | |
| SCHEMBL12563384 | 0.80 | L3MBTL3 (0.39) | SIGMAR1 | |
| SCHEMBL24827910 | 0.79 | MEN1 (0.36) | OPRM1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL23594119 | 0.79 | MEN1 (0.36) | OPRM1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL12395797 | 0.79 | SIGMAR1 (0.33) | OPRM1OPRK1OPRL1SIGMAR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, CD2, TYRO3 | OPRM1 400/4885OPRK1 478/4885OPRL1 736/4885 |
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ALK, CD2, TYRO3 | OPRM1 400/4885OPRK1 478/4885OPRL1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.